FY2030 Earnings Estimate for Valneva Issued By HC Wainwright

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities research analysts at HC Wainwright reduced their FY2030 earnings per share (EPS) estimates for shares of Valneva in a report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $3.78 for the year, down from their prior forecast of $3.84. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share.

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Valneva has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Price Performance

Shares of VALN stock opened at $10.49 on Friday. The stock has a market cap of $903.29 million, a price-to-earnings ratio of -6.64 and a beta of 1.80. The business’s fifty day moving average is $10.28 and its 200 day moving average is $9.67. Valneva has a twelve month low of $5.43 and a twelve month high of $12.25. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 1.52.

Institutional Trading of Valneva

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. bought a new position in Valneva during the 2nd quarter valued at approximately $8,240,000. Marex Group plc bought a new stake in Valneva in the second quarter worth $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva in the fourth quarter worth $94,000. JPMorgan Chase & Co. bought a new position in shares of Valneva during the third quarter valued at $124,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Valneva during the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.